ADMAX
Longer-acting Semax analog (Adamax) with extended duration of action. Used as an alternative to Semax when once-daily dosing is preferred. Very limited independent evidence beyond Semax mechanism extrapolation.
ADMAX (Adamax) is a longer-acting variant of Semax, modified to extend its duration of action. The primary pharmacokinetic advantage is extended half-life allowing once-daily dosing compared to the 2–3x daily dosing of Semax.
The mechanism is assumed to be similar to Semax — BDNF upregulation, neuroprotective effects — based on structural relationship. However, independent clinical or preclinical data for ADMAX specifically is extremely limited.
In physician practice, Joseph describes ADMAX as an alternative to Semax rather than a routine companion. It may be preferred when compliance with multiple daily doses is a concern, or when a smoother effect profile is desired.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
ADMAX has essentially no independent safety data from controlled human studies. The risk profile is unknown beyond inference from Semax pharmacology. Research use only. Not WADA-prohibited. Approach with significant caution given very limited data. All information for educational reference only.